Monthly Oncology Tumor Boards: Management of Patients with Multiple Myeloma

February 10, 2023

Studies with new drugs classes and new combination regimens have broadened the treatment options for multiple myeloma (MM). The integration of these novel regimens into the treatment paradigm has shifted the perception of MM from an incurable disease to a chronic one. Clinicians treating patients with MM are often faced with a difficult task of deciding who to treat, choosing optimal induction and maintenance therapies based on risk of recurrence and other factors, utilizing knowledge of previously administered therapies to treat relapses, etc. while taking into consideration patient co-morbidities, potential adverse events of therapies, and patient preferences. It is difficult for clinicians to remain current with the evolving treatment options for MM. In order to optimize overall patient outcomes, clinicians need to understand the evidence behind the current guidelines’ recommendations, the rationale for appropriate treatment selection, and the management of any treatment- or MM-specific adverse events.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Select individualized evidence-based strategies for treatment of patients with newly diagnosed MM.
  • Discuss supportive care measures needed for management of any myeloma or its treatment-related adverse effects.
  • Review the current and emerging therapeutic options for patients with relapsed/refractory MM.
Additional information

This activity is supported by educational grants from:

  • AstraZeneca
  • Coherus BioSciences
  • Exact Sciences
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Lilly
  • Novartis

This activity is supported by independent educational grants from:

  • Merck & Co., Inc.
  • Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.

This educational activity is supported by medical education grants from:

  • Exelixis, Inc.
  • Karyopharm Therapeutics
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
Course expires: 
Event starts: 
02/10/2023 - 12:30pm EST
Event ends: 
02/10/2023 - 1:30pm EST

Michaela Liedtke, MD
Stanford Cancer Institute

Surbhi Sidana, MD
Stanford Cancer Institute


NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Michaela Liedtke, MD
AbbVie, Inc.: Grant/Research Support 
Adaptive Scientific Advisor 
Allogene: Grant/Research Support 
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor Caelum: Grant/Research Support 
Gilead Sciences, Inc.: Grant/Research Support 
GlaxoSmithKline: Scientific Advisor 
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor Kite Pharma: Scientific Advisor
Kura Oncology, Inc.: Scientific Advisor 
Natera: Scientific Advisor
Seattle Genetics, Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor

Surbhi Sidana, MD
Allogene: Grant/Research Support
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fee; Grant/Research Support
Magenta Therapeutics: Consulting Fee; Grant/Research Support 
Oncopeptides: Consulting Fee
sanof-aventis U.S.: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-23-014-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour. Activity Code: I00053773; Approval #: 230000220

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation


Please login or register to take this course.

This webinar was presented live one time only on Friday, February 10, 2023, from 12:30 – 1:30 PM EST (UTC -5).
The recorded presentation is available here.


NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.

To access this policy including reporting procedures, please visit

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing